clinical trial · NCT06334432
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Pancreatic CancerPlatinum-resistant Ovarian Cancer (PROC)NUV-1511
brief summary
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
started
Mar 14, 2024
primary completion
Mar 1, 2027
completion
Oct 1, 2027
last updated
Jan 14, 2026
official title
A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol